Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SB751689 · 6 trials · 1 indication
| Name | Type | Description |
|---|---|---|
| SB-751689 | DRUG | - |
| SB-751689 oral tablets (100 and 400 ng) | DRUG | - |
| Ketoconazole (NIZORAL) oral tablets (200 mg) | DRUG | - |
| SB-751689 oral tablets (400 mg) | DRUG | - |
| SB751689 | DRUG | - |
Inclusion Criteria: * Healthy adult males or females between the ages of 21 and 55, inclusive, will be eligible for the study. Female subjects must be of non-childbearing potential including pre-menopausal females with documented (medical report verification) hysterectomy or bilateral oophorectomy ...
SB751689 is an investigational small-molecule drug candidate developed by GSK plc for osteoporosis. It has been studied in Phase 1 clinical trials, all of which are completed. It is not an approved medicine and remains in clinical development.
SB751689 is being investigated for the treatment of osteoporosis. Its clinical program has focused on postmenopausal women and healthy volunteers, including Japanese postmenopausal women. All six Phase 1 studies have been completed, and the drug has not been approved for any use.
SB751689 is developed by GSK plc, which trades under the ticker GSK. GSK sponsored the Phase 1 clinical program for the drug candidate in osteoporosis.
SB751689 is in Phase 1 clinical development. Six Phase 1 trials have been conducted and all are completed, with no active trials ongoing. The drug is investigational and has not received regulatory approval.
SB751689 has been evaluated in six completed Phase 1 trials, including NCT00554255 in Japanese postmenopausal women, NCT00540878 on formulation and absorption, NCT00508534 on esomeprazole interaction, and NCT00499928 on metabolism and excretion. Total enrollment across the program was 113 participants.
Yes, SB751689 and SB-751689 are the same drug candidate. It has also been referred to as SB-751689 oral tablets in 100 mg and 400 mg strengths, and in some listings as 100 and 400 ng. All names refer to the same GSK osteoporosis compound.